Search Results

Biocartis Group NV announces the publication of nine performance study abstracts of its fully automated molecular diagnostics Idylla™ platform1 and assays2 at the annual meeting of the ‘Association for Molecular Pathology’, a leading molecular diagnostics conference, taking place between 1-5 November in Phoenix, Arizona.

Biocartis Group NV announced that it has entered into an agreement with AstraZeneca aimed at the development and applicable pre-market notification or approval with the US FDA of a novel companion diagnostic1 test on Biocartis’ molecular rapid and easy-to-use diagnostics Idylla™ platform, for use with Tagrisso®, AstraZeneca’s third-generation EGFR-TKI treatment.

Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.

Genomic Health, Inc. and Biocartis Group NV today announced they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version of the Oncotype DX® Genomic Prostate Score® (GPS™) test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.

The Notification contains the following information:

Immunexpress, Pty Ltd. today announced the presentation of two posters evaluating SeptiCyte® RAPID at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) 2024, to take place from April 27 – 30 in Barcelona, Spain.

First commercially available reference standard for microsatellite instability (MSI) testing